32 results
8-K
EX-99.1
PRDS
Pardes Biosciences Inc
7 Nov 22
Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
4:00pm
financial resources necessary to continue its clinical trials and fund development goals and business operations; (iv) the impact of the COVID-19 pandemic
424B3
PRDS
Pardes Biosciences Inc
14 Sep 22
Prospectus supplement
8:06am
development goals and fund business operations; (iii) the impact of the COVID-19 pandemic on Pardes’ business, clinical trials, financial condition
8-K
EX-99.1
PRDS
Pardes Biosciences Inc
14 Sep 22
Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors
8:02am
its product candidates; (ii) Pardes’ ability to maintain financial resources necessary to continue its clinical trials, fund development goals
424B3
PRDS
Pardes Biosciences Inc
13 Sep 22
Prospectus supplement
8:05am
of clinical trials; (iii) the Company’s ability to maintain financial resources necessary to continue its clinical trials, fund development goals
8-K
pfy602ejz
13 Sep 22
Other Events
8:02am
8-K
EX-99.1
x447d74sdhhiu
15 Aug 22
Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
8:06am
424B3
3hhnjxz w5
9 Jun 22
Prospectus supplement
6:10am
8-K
s17id8087 zvh
9 Jun 22
Other Events
6:04am
8-K
EX-99.1
cujzq
10 May 22
Pardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
4:08pm
DEF 14A
4oalxcn7w9u2
26 Apr 22
Definitive proxy
6:07am
424B3
gaht6a 4q3
1 Apr 22
Prospectus supplement
4:01pm
POS AM
fd94 zgjmem49h91k2qz
30 Mar 22
Prospectus update (post-effective amendment)
7:32am
10-K
hqswy3iv pkd9p
29 Mar 22
Annual report
5:29pm
S-8
EX-99.3
z2zp8 8jfzm
2 Mar 22
Registration of securities for employees
4:33pm
424B3
9d2dueivq1 3esc
1 Feb 22
Prospectus supplement
5:03pm
8-K
xio2lhbeg
28 Jan 22
Departure of Directors or Certain Officers
4:05pm